Glycated Albumin and Cardiovascular Mortality in CKD Stage V Patients with Diabetes Mellitus: A Five-Year Follow-Up Study

Glycemic assessment in patients with chronic kidney disease (CKD) Stage V on hemodialysis (HD) is limited by the inaccuracy of hemoglobin A1c (HbA1c), mainly due to anemia, shortened erythrocyte lifespan, and erythropoiesis-stimulating agent (ESA) therapy. Glycated albumin (GA), independent of erythrocyte turnover, may better reflect glycemic exposure. We evaluated the diagnostic performance and clinical utility of GA as a biomarker of poor glycemic control and cardiovascular risk in patients with diabetes mellitus (DM). A cross-sectional analysis and five-year prospective follow-up were conducted in three subgroups: HD+DM+ (<i>n</i> = 40), HD- DM+ (<i>n</i> = 15), and HD+DM- (<i>n</i> = 22). Glycemic markers (mean plasma glucose over 3 months (PG<sub>3</sub>m), GA, and HbA1c) were compared between groups. GA levels were significantly higher in HD+DM+ patients (<i>p</i> < 0.001) and showed the strongest correlation with PG<sub>3</sub>m. GA independently predicted poor glycemic control (OR 3.23; 95% CI 1.54-6.77; <i>p</i> = 0.002) and demonstrated high diagnostic accuracy (AUC 0.873; optimal cut-off 10%). During the five-year follow-up, CV mortality was 35%, and 85% of deceased patients had GA > 10%. Although Cox regression did not reach statistical significance, GA showed a consistent trend toward higher CV mortality risk after adjustment for age and HD duration (HR 2.56; 95% CI 0.57-11.44; <i>p</i> = 0.21), whereas HbA1c was not prognostic (HR 1.39; 95% CI 0.49-3.91; <i>p</i> = 0.28). GA appears to be a clinically useful marker of glycemic control in diabetic patients with CKD Stage V receiving maintenance hemodialysis. In this cohort, GA showed high diagnostic accuracy and a more balanced sensitivity/specificity profile compared with HbA1c, with a consistent trend toward association with cardiovascular mortality. In this regard, the wider use of this marker in clinical practice is worth considering. Nevertheless, larger prospective studies are warranted to validate these observations.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-02-26
DOI
https://doi.org/10.3390/ijms27052215
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Glycated Albumin and Cardiovascular Mortality in CKD Stage V Patients with Diabetes Mellitus: A Five-Year Follow-Up Study

Radomir Naumović, Aleksandar Janković, Tatjana Damjanović, Bojan Stopić et al.
International Journal of Molecular Sciences
Chronic Kidney Disease and Diabetes
article

Glycated Albumin and Cardiovascular Mortality in CKD Stage V Patients with Diabetes Mellitus: A Five-Year Follow-Up Study

Radomir Naumović, Aleksandar Janković, Tatjana Damjanović, Bojan Stopić, Nada Dimković, Jelena Bjedov, Svetlana Jelić, Verica Todorov-Sakić, Petar Đurić, Ana Bulatovic
article en

Abstract

Glycemic assessment in patients with chronic kidney disease (CKD) Stage V on hemodialysis (HD) is limited by the inaccuracy of hemoglobin A1c (HbA1c), mainly due to anemia, shortened erythrocyte lifespan, and erythropoiesis-stimulating agent (ESA) therapy. Glycated albumin (GA), independent of erythrocyte turnover, may better reflect glycemic exposure. We evaluated the diagnostic performance and clinical utility of GA as a biomarker of poor glycemic control and cardiovascular risk in patients with diabetes mellitus (DM). A cross-sectional analysis and five-year prospective follow-up were conducted in three subgroups: HD+DM+ (<i>n</i> = 40), HD- DM+ (<i>n</i> = 15), and HD+DM- (<i>n</i> = 22). Glycemic markers (mean plasma glucose over 3 months (PG<sub>3</sub>m), GA, and HbA1c) were compared between groups. GA levels were significantly higher in HD+DM+ patients (<i>p</i> < 0.001) and showed the strongest correlation with PG<sub>3</sub>m. GA independently predicted poor glycemic control (OR 3.23; 95% CI 1.54-6.77; <i>p</i> = 0.002) and demonstrated high diagnostic accuracy (AUC 0.873; optimal cut-off 10%). During the five-year follow-up, CV mortality was 35%, and 85% of deceased patients had GA > 10%. Although Cox regression did not reach statistical significance, GA showed a consistent trend toward higher CV mortality risk after adjustment for age and HD duration (HR 2.56; 95% CI 0.57-11.44; <i>p</i> = 0.21), whereas HbA1c was not prognostic (HR 1.39; 95% CI 0.49-3.91; <i>p</i> = 0.28). GA appears to be a clinically useful marker of glycemic control in diabetic patients with CKD Stage V receiving maintenance hemodialysis. In this cohort, GA showed high diagnostic accuracy and a more balanced sensitivity/specificity profile compared with HbA1c, with a consistent trend toward association with cardiovascular mortality. In this regard, the wider use of this marker in clinical practice is worth considering. Nevertheless, larger prospective studies are warranted to validate these observations.

International Journal of Molecular SciencesVol. 27(5)
Serbian Academy of Sciences and Arts (RS), University of Belgrade (RS), Kliničko Bolnički Centar Zvezdara (RS)
Good health and well-being
Openalex Percentile: Top 49%
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.